Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camoteskimab Phase 2b study in adults with moderate-to-severe atopic dermatitis
2026-525673-39-00Phase 2Authorised
- Sponsor
- Apollo Therapeutics
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Camoteskimab with Placebo (2 arms). Primary endpoint: Percentage change from baseline in EASI at Week 24. Planned start Sep 2026; status: authorised.
02
Drugs
camoteskimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2026-525673-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525673-39-00.